TORONTO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/FSDDF?src=hash" target="_blank"gt;#FSDDFlt;/agt;–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the
“Company”), today announced the appointment of pharmaceutical industry
leader, Edward J. Brennan, Jr., M.D., FACS, as President of its
biosciences division. Dr. Brennan has more than 25 years’ experience in
leadership roles at major pharmaceutical companies and clinical research
organizations.
“Ed is an accomplished biopharmaceutical executive with a proven track
record in FDA submissions and drug development,” said Dr. Raza Bokhari,
FSD Executive Co-Chairman & Chief Executive Officer. “We aim
to capitalize on his expert guidance as FSD builds on our recently
announced acquisition of Prismic Pharmaceuticals and continues to
execute on our strategy to identify and acquire
cannabinoid-based pharmaceutical R&D companies focused on FDA approved
clinical trials.”
“Leading FSD’s Biosciences Division is a very exciting opportunity for
me. The company’s paradigm shift to unlock the promise of the synthetic
cannabinoid molecule is bold but timely,” said Dr. Brennan. “I look
forward to leading the company’s team in realizing our vision to advance
R&D of FDA-approved synthetic cannabinoids and other synergistic
molecules.”
Dr. Brennan has extensive experience in all phases of clinical
development across multiple therapeutic areas. As a Medical Director
with Wyeth-Ayerst Research and GlaxoSmithKline, he led teams through
ten IND applications and advanced multiple compounds from pre-candidate
selection (proof of concept) through clinical trial management and
approval. At GSK, he was also responsible for coordinating all clinical
activities for external partners within its Center of Excellence in
External Drug Discovery. He next founded IndiPharm, a full-service
global CRO, that was eventually acquired by private equity company,
Velocity Fund Partners.
Dr. Brennan received his undergraduate Bachelor of Science Degree in
Pharmacy from the Philadelphia College of Pharmacy and Science. He went
on to study Medicine at the Royal College of Surgeons in Ireland before
receiving his medical degree from the Temple University School of
Medicine.
About FSD Pharma
FSD Pharma is focused on the development of the highest quality indoor
grown, pharmaceutical grade cannabis and on the research and development
of novel cannabinoid-based treatments for several central nervous system
disorders, including chronic pain, fibromyalgia and irritable bowel
syndrome. The Company has 25,000 square feet that is licensed at its
Ontario facility and expansion is currently underway.
FSD facilities sit on 70 acres of land with 40 acres primed for
development with an expansion plan of up to 3,896,000 square feet by
2025.
FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under
the Cannabis Act and Regulations, having received its cultivation
license on October 13, 2017 and its Sale for Medical Purposes license on
April 18, 2019. FV Pharma’s vision is to transform its current
headquarters in a Kraft plant in Cobourg, Ontario into the largest
hydroponic indoor grow facility in the world. FV Pharma intends to cover
all aspects of this exciting new industry, including cultivation, legal,
processing, manufacturing, extracts and research and development.
Forward-Looking Information
Neither the Canadian Securities Exchange nor its regulation services
provider accept responsibility for the adequacy or accuracy of this
release.
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words “could”,
“intend”, “expect”, “believe”, “will”, “projected”, “estimated” and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information
and are based on FSD Pharma’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may
differ materially. Actual results and developments may differ materially
from those contemplated by these. The forward-looking information
contained in this press release is made as of the date hereof, and FSD
Pharma is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events or
otherwise, except as required by applicable securities laws. Because of
the risks, uncertainties and assumptions contained herein, investors
should not place undue reliance on forward looking-information. The
foregoing statements expressly qualify any forward-looking information
contained herein.
Contacts
Investor Relations
Email: IR@fsdpharma.com
Website:
www.fsdpharma.com
Media
Relations
Ned Berkowitz
Email: Ned.Berkowitz@russopartnersllc.com
Tel:
(646) 942-5629
Zeeshan Saeed, President and Founder, FSD
Pharma Inc.
Email: zeeshan@fsdpharma.com
Telephone:
(416) 854-8884